(Reuters) -Praxis Precision Medicines said on Thursday its experimental drug for movement disorder helped patients improve their ability to perform daily tasks in two late-stage trials, sending its shares surging more than twofold before the bell.

The company was testing the drug, ulixacaltamide, in adults with essential tremor, a nervous system condition that causes involuntary shaking, primarily affecting the hands and arms. The condition currently has no approved treatments designed specifically for it.

The first study, which enrolled 473 patients, showed that the drug helped improve daily functioning by 4.3 points on a commonly used scale, compared to placebo.

In the second trial, patients showed superior maintenance of effect while on ulixacaltamide compared to those who switched t

See Full Page